Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DATO-BASE: Datopotamab-deruxtecan for Breast Cancer Brain Metastases
NCT06176261Phase 2Recruiting
- Sponsor
- Nancy Lin
- Start
- Jan 2024
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of datopotamab deruxtecan in breast cancer, sponsored by Nancy Lin. Started Jan 2024; status: recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06176261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06176261.